Soamnauth Misir

597 total citations
22 papers, 462 citations indexed

About

Soamnauth Misir is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Surgery. According to data from OpenAlex, Soamnauth Misir has authored 22 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Oncology and 4 papers in Surgery. Recurrent topics in Soamnauth Misir's work include Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers), Diabetes Treatment and Management (6 papers) and Lipoproteins and Cardiovascular Health (4 papers). Soamnauth Misir is often cited by papers focused on Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers), Diabetes Treatment and Management (6 papers) and Lipoproteins and Cardiovascular Health (4 papers). Soamnauth Misir collaborates with scholars based in United States, United Kingdom and Germany. Soamnauth Misir's co-authors include Sukumar Nagendran, Stacey L. Abby, Michael R. Jones, Jianbo Xu, Ronald Goldberg, Yehuda Handelsman, Julio Rosenstock, Ishwarlal Jialal, Yu‐Ling Lai and Xiaoping Jin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Soamnauth Misir

22 papers receiving 451 citations

Peers

Soamnauth Misir
Li‐Chiu Wu Taiwan
Anca Zimmermann Germany
Ylva Bonde Sweden
Kalpna Desai United Kingdom
Gennaro Clemente Italy
Juanwen Zhang China
Devin Abrahami Canada
Soichiro Saikawa Japan
Elisa Pellegrini Italy
Li‐Chiu Wu Taiwan
Soamnauth Misir
Citations per year, relative to Soamnauth Misir Soamnauth Misir (= 1×) peers Li‐Chiu Wu

Countries citing papers authored by Soamnauth Misir

Since Specialization
Citations

This map shows the geographic impact of Soamnauth Misir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soamnauth Misir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soamnauth Misir more than expected).

Fields of papers citing papers by Soamnauth Misir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soamnauth Misir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soamnauth Misir. The network helps show where Soamnauth Misir may publish in the future.

Co-authorship network of co-authors of Soamnauth Misir

This figure shows the co-authorship network connecting the top 25 collaborators of Soamnauth Misir. A scholar is included among the top collaborators of Soamnauth Misir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soamnauth Misir. Soamnauth Misir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Avutu, Viswatej, Emily K. Slotkin, Sant P. Chawla, et al.. (2022). A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.. Journal of Clinical Oncology. 40(16_suppl). TPS11584–TPS11584. 3 indexed citations
4.
Wirth, Lori J., Marcia S. Brose, Eric J. Sherman, et al.. (2021). Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. Journal of Clinical Oncology. 39(21). 2359–2366. 83 indexed citations
5.
Wirth, Lori J., Marcia S. Brose, Eric J. Sherman, et al.. (2020). MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC). Journal of the Endocrine Society. 4(Supplement_1). 3 indexed citations
6.
Smith, John W., Karen L. Tedesco, Soamnauth Misir, et al.. (2019). Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer. Clinical Breast Cancer. 20(2). 160–167. 4 indexed citations
7.
8.
9.
Tolaney, SM, Kevin Kalinsky, Virginia Kaklamani, et al.. (2018). Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Cancer Research. 78(4_Supplement). PD6–13. 56 indexed citations
10.
Rosenstock, Julio, et al.. (2012). Initial Combination Therapy with Metformin plus Colesevelam in Drug-Naïve Hispanic Patients with Early Type 2 Diabetes. Postgraduate Medicine. 124(4). 7–13. 6 indexed citations
11.
Goldberg, Ronald, et al.. (2012). Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diabetes and Vascular Disease Research. 10(3). 256–262. 6 indexed citations
12.
Rosenstock, Julio, et al.. (2012). Clinical Effects of Colesevelam in Hispanic Subjects with Primary Hyperlipidemia and Prediabetes. Postgraduate Medicine. 124(4). 14–20. 5 indexed citations
13.
Goldberg, Ronald, et al.. (2012). Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. Journal of clinical lipidology. 6(4). 318–324. 11 indexed citations
14.
Schwartz, Sherwyn, Yu‐Ling Lai, Jianbo Xu, et al.. (2010). The Effect of Colesevelam Hydrochloride on Insulin Sensitivity and Secretion in Patients With Type 2 Diabetes: A Pilot Study. Metabolic Syndrome and Related Disorders. 8(2). 179–188. 40 indexed citations
15.
Davidson, Michael H., Joanne M. Donovan, Soamnauth Misir, & Michael R. Jones. (2010). A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia. American Journal of Cardiovascular Drugs. 10(5). 305–314. 18 indexed citations
16.
Rosenstock, Julio, Vivian Fonseca, W. Timothy Garvey, et al.. (2010). Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. Endocrine Practice. 16(4). 629–640. 31 indexed citations
17.
Handelsman, Yehuda, Ronald Goldberg, W. Timothy Garvey, et al.. (2010). Colesevelam Hydrochloride to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study. Endocrine Practice. 16(4). 617–628. 31 indexed citations
18.
Jialal, Ishwarlal, Stacey L. Abby, Soamnauth Misir, & Sukumar Nagendran. (2009). Concomitant Reduction in Low-Density Lipoprotein Cholesterol and Glycated Hemoglobin With Colesevelam Hydrochloride in Patients With Type 2 Diabetes: A Pooled Analysis. Metabolic Syndrome and Related Disorders. 7(3). 255–258. 28 indexed citations
19.
Stein, Evan A., A. David Marais, Tamás Szamosi, et al.. (2009). Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects with Heterozygous Familial Hypercholesterolemia. The Journal of Pediatrics. 156(2). 231–236.e3. 52 indexed citations
20.
Jones, Michael R., Sunder Mudaliar, AG Unnikrishnan, et al.. (2009). Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Current Medical Research and Opinion. 25(9). 2239–2249. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li‐Chiu Wu Breakdown of academic impact, for papers by Anca Zimmermann Breakdown of academic impact, for papers by Ylva Bonde Breakdown of academic impact, for papers by Kalpna Desai Breakdown of academic impact, for papers by Gennaro Clemente Breakdown of academic impact, for papers by Juanwen Zhang Breakdown of academic impact, for papers by Devin Abrahami Breakdown of academic impact, for papers by Soichiro Saikawa Breakdown of academic impact, for papers by Elisa Pellegrini
Rankless by CCL
2026